Innovent Biologics (HKEX: 01801) announced that the first patient has been dosed in a pivotal Phase 3 clinical trial, designated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE